PAMA Reporting Delayed Again as Permanent Fix Sought Labs received a welcome reprieve from looming Clinical Lab Fee Schedule (CLFS) cuts this month when Protecting Access to Medicare Act (PAMA) reporting and associated test reimbursement reductions were delayed until...
The 2024 Medicare Physician Fee Schedule Proposed Rule released July 13 is already generating pushback from lab and pathology advocates, such at the College of American Pathologists (CAP), who contend these services and the physicians who provide them cannot sustain...
Independent laboratories have been pushed to the brink of financial instability in recent years due to the price cuts mandated by the Protecting Access to Medicare Act of 2014 (PAMA). However, as part of a yearslong effort to rectify the problematic pricing and...
Clinical laboratories and healthcare providers as a whole received a number of welcome reprieves from potential payment cuts and burdensome regulation as 2022 drew to a close. But that doesn’t mean many of these issues couldn’t be resurrected in a different form in...
In a win for laboratory innovation, the VALID Act, which would have created a new risk-based framework for regulating lab developed tests (LDTs), was excluded from the year-end omnibus spending package recently finalized by Congress, meaning the legislation...
The 2023 Medicare Physician Fee Schedule Proposed Rule was released late Thursday, July 7. After two consecutive years of a Congress delaying a number of anticipated reimbursement cuts due to the impact of the COVID pandemic, it now appears some of these previously...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy